Results
Cohance Lifesciences FY26 Revenue Declines 13% YoY
Cohance Lifesciences reported FY26 revenue of ₹22.68 billion, a 13% YoY decline, with adjusted EBITDA margin at 21%.
Pharma CDMO revenue was ₹8.89 billion, impacted by destocking in two large commerci
